“Bimekizumab Versus Secukinumab Continuous Maintenance of PASI 90 and PASI 100 Responses through One Year in Patients With Moderate to Severe Plaque Psoriasis: Post-HOC Results from the BE RADIANT Phase 3b Trial”. 2024. SKIN The Journal of Cutaneous Medicine 8 (2): s403. https://doi.org/10.25251/skin.8.supp.403.